Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MD-0727 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| MD-0727 | DRUG | - |
Inclusion Criteria: * Patient is male or non-pregnant, non-breastfeeding female, at least 18 years of age * Patient must agree to use contraception and/or birth control if sexually active * Patient may not be on lipid-lowering therapies at least 6 weeks prior to study and must have a fasting LDL-C ...
Top 12 of 15 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 4 | PHASE3 | Enlicitide |
| Novartis AG Sponsored ADR | NVS | 14 | PHASE3 | Inclisiran, Pelacarsen, DII235, QCZ484 |
| AstraZeneca PLC | AZN | 3 | PHASE3 | AZD0780, Laroprovstat, Rosuvastatin |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 5 | PHASE3 | Plozasiran, zodasiran, VSA003 |
| Ionis Pharmaceuticals, Inc. | IONS | 2 | PHASE3 | Olezarsen, ION775 |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE2 | Alirocumab |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Solbinsiran |
| MediciNova, Inc. | MNOV | 1 | PHASE2 | MN-001 |
| Verve Therapeutics, Inc. | VERV | 4 | PHASE2 | VERVE-102, VERVE-201 |
| NewAmsterdam Pharma Company N.V. | NAMS | 1 | PHASE1 | Obicetrapib |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX310 |
| Esperion Therapeutics, Inc. | ESPR | 1 | - | Bempedoic acid+ Ezetimibe |
MD-0727 is an investigational small molecule being developed for the treatment of hypercholesterolemia, a condition characterized by high levels of cholesterol in the blood. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
MD-0727 is being developed by Ironwood Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol IRWD. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with hypercholesterolemia.
MD-0727 is in Phase 2 clinical development. It is an investigational drug and has not yet received regulatory approval. A Phase 2 clinical trial has been completed, and the drug is not currently in active clinical trials.
MD-0727 has been studied in one completed Phase 2 clinical trial, identified as NCT00404001. This trial, titled 'Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia,' enrolled 150 participants in the United States and was a randomized, double-blind study.
MD-0727 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development. The completed Phase 2 trial (NCT00404001) evaluated the drug in patients with hypercholesterolemia, but the drug has not yet been approved for any use.